{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T12:35:40Z","timestamp":1724416540354},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Except for neurotrophin, no drug had an indication for postherpetic neuralgia (<jats:styled-content style=\"fixed-case\">PHN<\/jats:styled-content>) in Japan prior to pregabalin approval. This approval might have changed <jats:styled-content style=\"fixed-case\">PHN<\/jats:styled-content> treatment patterns. This study aimed to compare <jats:styled-content style=\"fixed-case\">PHN<\/jats:styled-content> treatment patterns and medical costs between patients who started treatment before and after pregabalin approval. Japanese claims data were used to identify patients aged 18 years or more with <jats:styled-content style=\"fixed-case\">PHN<\/jats:styled-content>, postherpetic trigeminal neuralgia or postherpetic polyneuropathy who were initiated on their first <jats:styled-content style=\"fixed-case\">PHN<\/jats:styled-content>\u2010associated prescription through May 2010 (before approval) or from June 2010 (after approval). From these claims, 6\u2010month treatment patterns from first prescription were compared for the periods before and after approval. These patterns included pain\u2010related medications and the frequency of pain\u2010relief procedures. All\u2010cause and pain\u2010related medical costs were also compared for these periods. The number of <jats:styled-content style=\"fixed-case\">PHN<\/jats:styled-content> patients who were initiated on treatment before and after approval were 107 (mean age, 47.4 \u00b1 13.0 years) and 505 (45.9 \u00b1 13.0), respectively. Post\u2010approval, significant reductions were observed for prescription of non\u2010steroidal anti\u2010inflammatory drugs, tricyclic antidepressants and neurotrophin relative to before approval. Excluding pregabalin acquisition costs, mean costs per patient for medications associated with <jats:styled-content style=\"fixed-case\">PHN<\/jats:styled-content> for 6 months from the first prescription were significantly lower after approval, \u00a52882 vs \u00a54185. Total medical costs were similar in both periods. Approval of pregabalin appeared to result in a treatment paradigm toward use of an approved therapy with demonstrated efficacy.<\/jats:p>","DOI":"10.1111\/1346-8138.13784","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T10:32:50Z","timestamp":1488537170000},"page":"767-773","source":"Crossref","is-referenced-by-count":8,"title":["Treatment patterns of postherpetic neuralgia patients before and after the launch of pregabalin and its effect on medical costs: Analysis of Japanese claims data provided by Japan Medical Data Center"],"prefix":"10.1111","volume":"44","author":[{"given":"Mariko","family":"Honda","sequence":"first","affiliation":[{"name":"Dr Mariko Skin and Dermatology Clinic Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Murata","sequence":"additional","affiliation":[{"name":"Crecon Medical Assessment Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Ebata","sequence":"additional","affiliation":[{"name":"Pfizer Japan Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Fujii","sequence":"additional","affiliation":[{"name":"Pfizer Japan Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Setsuro","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Nihon University Research Center Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"295","article-title":"Visual review, herpes zoster [Japanese]","volume":"31","author":"Nimura M","year":"2001","journal-title":"Infect Inflamm Immun"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1533-2500.2007.00164.x"},{"key":"e_1_2_7_4_1","unstructured":"IASP Taxonomy. [Accessed 8 July 2015.] Available from URL athttp:\/\/www.iasp-pain.org\/Education\/Content.aspx?ItemNumber=1698."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2009.0649"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02999.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.09.008"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055433.55136.55"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.01.001"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2008.00423.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X80404"},{"key":"e_1_2_7_12_1","first-page":"141","article-title":"Efficacy and tolerability of pregabalin for postherpetic neuralgia: a multicenter, randomized, double\u2010blind, placebo\u2010controlled clinical trial","volume":"17","author":"Ogawa S","year":"2010","journal-title":"J Japan Soc Pain Clin"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-8-33"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000145767.36287.A1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2004.12.007"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2004.05.001"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2007.05.003"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2005.02.032"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2105"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03152.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1086-1"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000244422.45278.ff"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2007.06.033"},{"key":"e_1_2_7_24_1","volume-title":"Guideline for the Pharmacologic Management of Neuropathic Pain","author":"Japan Society of Pain Clinicians","year":"2011"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20090066"},{"key":"e_1_2_7_26_1","volume-title":"Guidebook for the Treatment of Neuropathic Pain","author":"Ogawa S","year":"2010"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S71976"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2015.03.006"},{"key":"e_1_2_7_29_1","first-page":"25","article-title":"Risk of stroke associated with nonsteroidal anti\u2010inflammatory drugs","volume":"10","author":"Park K","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_7_30_1","unstructured":"FDA Drug Safety Communication: FDA strengthens warning that non\u2010aspirin nonsteroidal anti\u2010inflammatory drugs (NSAIDs) can cause heart attacks or strokes.2015. (Accessed September 16 2015 at FDA Drug Safety Communication: FDA strengthens warning that non\u2010aspirin nonsteroidal anti\u2010inflammatory drugs (NSAIDs) can cause heart attacks or strokes.)"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21599"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2753.2011.01752.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.3820\/jjpe.16.1"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:36:36Z","timestamp":1695573396000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/1346-8138.13784"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13784","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}